Wolf J, Seto T, Han JY, et al. - In patients with MET-dysregulated advanced non–small-cell lung cancer, researchers tested capmatinib (a selective inhibitor of the MET receptor) (NSCLC), via this multiple-cohort, phase 2 study. They allocated 364 patients to cohorts based on previous lines of treatment and MET status (MET exon 14 skipping mutation or MET amplification as per gene copy number in tumor tissue). Patients were administered capmatinib (400-mg tablet) twice daily. In patients with advanced NSCLC with a MET exon 14 skipping mutation, substantial antitumor activity was seen with capmatinib, especially in those not treated before. A higher efficacy in MET-amplified advanced NSCLC was evident in tumors with a high gene copy number vs in those with a low gene copy number. The chief toxic impacts were low-grade peripheral edema and nausea.